Last reviewed · How we verify
Efavirenz, tenofovir disoproxil fumarate and emtricitabine
Efavirenz, tenofovir disoproxil fumarate and emtricitabine is a Small molecule drug developed by Laboratorio Elea Phoenix S.A.. It is currently FDA-approved.
At a glance
| Generic name | Efavirenz, tenofovir disoproxil fumarate and emtricitabine |
|---|---|
| Sponsor | Laboratorio Elea Phoenix S.A. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection (PHASE1)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Efavirenz, tenofovir disoproxil fumarate and emtricitabine CI brief — competitive landscape report
- Efavirenz, tenofovir disoproxil fumarate and emtricitabine updates RSS · CI watch RSS
- Laboratorio Elea Phoenix S.A. portfolio CI
Frequently asked questions about Efavirenz, tenofovir disoproxil fumarate and emtricitabine
What is Efavirenz, tenofovir disoproxil fumarate and emtricitabine?
Efavirenz, tenofovir disoproxil fumarate and emtricitabine is a Small molecule drug developed by Laboratorio Elea Phoenix S.A..
Who makes Efavirenz, tenofovir disoproxil fumarate and emtricitabine?
Efavirenz, tenofovir disoproxil fumarate and emtricitabine is developed and marketed by Laboratorio Elea Phoenix S.A. (see full Laboratorio Elea Phoenix S.A. pipeline at /company/laboratorio-elea-phoenix-s-a).
What development phase is Efavirenz, tenofovir disoproxil fumarate and emtricitabine in?
Efavirenz, tenofovir disoproxil fumarate and emtricitabine is FDA-approved (marketed).